Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 2(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04620590Phase 4Completed

Dapagliflozin Treatment in Type 2 Diabetes

Role: collaborator

NCT01304316Phase 2Completed

Dose-Escalation Safety and Pharmacokinetic Study of K305

Role: collaborator

NCT01302483Phase 2Completed

Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia

Role: collaborator

All 3 trials loaded